Introduction
============

For males worldwide, prostate cancer (PCa) has the second highest incidence of all cancers. Each year, approximately 238,590 new cases and 29,720 deaths are reported according to cancer statistics, 2013. In view of the anfractuous pathogenesis of PCa, interconnected cell signaling pathways and transmissions which manipulates the survival, evolution and apoptosis of cells[@B1]-[@B3], would provide us new inspirations of the prevention and treatment of PCa patients.

Among diverse pathways, genes encompassed in phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, such as toll-like receptor-4 (*TLR4*), vascular endothelial growth factor (*VEGF*), interleukin 6 (*IL-6*), insulin receptor substrate 1 (*IRS1*) and insulin-like growth factor 1 (IGF1), appear with more common mutations or amplifications in PCa (**Figure [S1](#SM0){ref-type="supplementary-material"}** and**Figure [S2](#SM0){ref-type="supplementary-material"}**). PI3K is a phosphatidylinositol kinase which is encoded by the *PIK3CA* gene. It consists of a catalytic subunit p110 and regulatory subunit p85. Akt is a cytoplasmic serine-threonine protein kinase which promotes the progression of cell cycle and inhibits cell apoptosis. The PI3K/Akt signaling pathway is implicated in different cellular functions, including survival, growth, proliferation, metabolism and angiogenesis. Currently, the relationships between polymorphisms in genes of PI3K/Akt signaling pathway and PCa risk have been an area of intense investigations but with mixed results[@B4],[@B5]. For instance, Balistreri *et al.*[@B6] pointed out that there existed a significant association between polymorphisms in *TRL4* and an increased risk of PCa, a result consistent with both Wang *et al.*\'s[@B7] and Chen *et al.*\'s[@B8] work. However, Shui *et al.*[@B9] has conducted a case-control study comprising 1,267 controls and 1,286 PCa cases and found that genetic variation across *TLR4* alone is not strongly associated with PCa risk. As for polymorphisms in *IGF1*, Schildkraut *et al.*[@B10] revealed the significant association between genetic polymorphisms in *IGF1* and PCa risk among Black and White men. On the contrary, Neuhausen *et al.*[@B11] failed to find any positive connection between *IGF1* polymorphisms and PCa risk. In addition, for *IL-6*-rs1800795, both Kesarwani *et al.*[@B12] and Mandal *et al.*\'s[@B13] studies supported the role of *IL-6*-rs1800795 polymorphism in PCa, while the result was inconsistent with Bao *et al.*\'s[@B14] work.

Hence, previous studies had presented inconsistent views between polymorphisms encompassed in genes of PI3K/Akt signaling pathway and PCa risk. Considering that, we conducted the current updated meta-analysis in order to precisely evaluate their associations on the foundation of all available eligible studies, providing with convincible evidence for the prevention and/or targeted therapy for PCa patients.

Material and Methods
====================

Acquisition of the PI3K/Akt Pathway Gene Set
--------------------------------------------

The gene set of PI3K/Akt pathway was referenced to the Kyoto Encyclopedia of Genes and Genomes (KEGG) website (<http://www.kegg.jp/kegg-bin/show_pathway?hsa04151>). The gene set was originally provided via the KEGG signaling database, and encompassed the following 101 genes: *ANGPT2*,*ANGPT4*,*IL2RB*,*CD19*,*COL1A*,*IL3*, *COL2A*,*IL3RA*,*COL4A*,*COL6A*,*IL6*,*COL9A*,*CSF1*,*CSF1R*,*CSF3*,*CSF3R*,*EFNA*,*EGF*,*EGFR*,*EPHA2*,*EPO*,*EPOR*,*FGF*,*FGF1*,*FGF2*,*FGFR1*,*FGFR2*,*FGFR3*,*FGFR4*,*FLT1*,*FLT4*,*GH*,*GHR*,*IL6R*,*GRB2*,*HGF*,*HRAS*,*IFNA*,*IFNAR1*,*IFNAR2*,*IFNB*,*IGF1*,*IGF1R*,*IGH*,*IL2*,*IL2RA*,*IL2RG*,*IL4*,*IL4R*,*IL7*,*IL7R*,*INS*,*INSR*,*IRS1*,*JAK1*,*JAK2*,*JAK3*,*KDR*,*KIT*,*KITLG*,*KRAS*,*LAMA1_2*,*LAMA3_5*,*LAMA4*,*LAMB1*,*LAMB2*,*LAMB3*,*LAMB4*,*LAMC1*,*LAMC2*,*MAP2K1*,*MAP2K2*,*MAPK1*,*MAPK2*,*MAPK3*,*MET*,*NGFA*,*NGFB*,*NGFR*,*NRAS*,*OSM*,*OSMR*,*PDGFA*,*PDGFB*,*PDGFC_D*,*PDGFRA*,*PDGFRB*,*PGF*,*PIK3AP1*,*PRL*,*PRLR*,*RAC1*,*RAF1*,*SOS*,*SYK*,*TEK*,*TLR2*,*TLR4*,*VEGFA*,*VEGFB* and*VEGFC-D*.

Study Description
-----------------

To evaluate the connections between polymorphisms in genes of PI3K/Akt pathway and PCa risk, we conducted the present study by combining all accessible studies together from diverse databases, including Web of Science, PubMed, and China National Knowledge Infrastructure (CNKI) databases. The integrated keywords were: (\'genes\' OR \'abbreviations of genes\') AND (\'cancer\' OR \'tumor\' OR \'carcinoma\' OR \'neoplasms\') AND (\'polymorphism\' OR \'mutation\' OR \'variant\' OR \'SNP\' OR \'genotype\'). At the same time, we used the integrated keywords (Gene_ID & prostate cancer) to search on Google, and performed the hand screening from all highly connected results. Besides, extra studies were collected via the reference lists of the identified studies. The final date of retrieval was in October 1, 2017. The whole studies in the analysis were firstly published in the primary literature with no reproduction in other studies.

Inclusion and Exclusion Criteria
--------------------------------

The inclusion criteria in this analysis were: (1) the cases were PCa patients and the controls were no history of cancers; 2) cohort studies or case-control studies concerning the relationships between polymorphisms in genes of PI3K/Akt signaling pathway and PCa risk; (3) the raw data of genotype frequency can be extracted. The exclusion criteria were as follows: (1) the raw data were not accessible; (2) case-only studies that didn\'t have control groups; (3) family-based association studies; and (4) Review papers.

Data Extraction
---------------

All of the data extraction work should be completed independently by 2 of the authors according to the prelisted inclusion criteria. And the arguments should be solved by another expert(s). You didn\'t mention the procedure in your article. In addition, we extracted data from each case-control study, including genotype frequencies, name of first author; year of publication; ethnicity and number of cases and controls. In addition, we used The Newcastle-Ottawa Scale (NOS) to evaluate the quality of enrolled studies.

Statistical analysis
--------------------

The meta-analysis was conducted to assess the associations between polymorphisms in genes of PI3K/Akt pathway and PCa risk. Hardy-Weinberg equilibrium (HWE) in the control group was tested[@B15]. To make a more comprehensive meta-analysis, five genetic models were adopted, including allele contrast (M vs. W), codominant (MM vs. WW and MW vs. WW), dominant (MM + MW vs. WW) and recessive models (MM vs. MW + WW). The impact of relationship was evaluated by odds ratio (OR) with a corresponding 95% confidential intervals (95%CI). What\'s more, when the heterogeneity (*P* \> 0.1 as the standard) [@B16] was assessed, the I[@B2]-based Q statistic was used (I[@B2] = 0-25%: no heterogeneity; I[@B2] = 25%-50%: moderate heterogeneity; I[@B2] = 50%-75%: large heterogeneity; I[@B2] = 75%-100%: extreme heterogeneity) [@B17], which represented the weighted sum of the squared difference between the overall effect size and the effect size from every study. When I[@B2] \> 50% or *P*~Q~ ≤ 0.1, substantial heterogeneity was existed, then, a random-effects model was used; otherwise, the fixed-effects model was be applied. It has been recognized that when results of the component studies differ among themselves, random effects incorporate an estimate of the inter-study variance and provide wider 95%CIs[@B18]. The analyses were conducted using Stata 12.0 (Stata Corporation, USA), and all *P* values were two-tailed.

Results
=======

Main Characteristics of the Enrolled Studies
--------------------------------------------

After initial screening, there were 1,166 results related to the search words enrolled. After reading the important information such as the titles and abstracts, 51 potential eligible studies were selected for next step full-text view. When a further screening was conducted, 13 of these studies were excluded for not associated with PCa risk. Finally, 38 articles with 62 case-control studies were left for data extraction (**Table [1](#T1){ref-type="table"}**) [@B12],[@B19]-[@B54].

Of them, there were 2,170 cases and 1,587 controls for *TLR4*-rs1927914 polymorphism (from three studies), 3,842 cases and 3,143 controls for *TLR4*-rs10759932 polymorphism (from 4 studies), 3,508 cases and 2,960 controls for *TLR4*-rs2149356 polymorphism (from 4 studies), 1,467 cases and 1,551 controls for *TLR4*-rs4986790 polymorphism (from 4 studies), 3,985 cases and 3,438 controls for *TLR4*-rs11536889 polymorphism (from 5 studies), 2,380 cases and 2,357 controls for *TLR4*-rs7873784 polymorphism (from 3 studies), 632 cases and 685 controls for *VEGF*-rs833061 polymorphism (from three studies), 1,511 cases and 821 controls for *VEGF*-rs1570360 polymorphism (from three studies), 1,243 cases and 1,620 controls for *IRS1*-rs1801278 polymorphism (from four studies), 2,289 cases and 2,114 controls for *FGFR4*-rs351855 polymorphism (from three studies), 1,805 cases and 3,235 controls for *IL-6*-rs1800796 polymorphism (from three studies), 10,625 cases and 12,353 controls for *IL-6*-rs1800795 polymorphism (from eight studies), 2,217 cases and 2,471 controls for *IGF1*-(CA) 19 polymorphism (from seven studies), respectively. In addition, the study selection processes for these polymorphisms were showed in **Figure [S3](#SM0){ref-type="supplementary-material"}-8**.

Furthermore, of the 62 case-control studies, 41 sets were performed on Caucasian populations, seven sets on Asian populations, six sets on African populations, and the other eight were based on mixed ethnic groups (including at least one race). Controls of 42 studies were population-based (P-B), while the other 20 studies were hospital-based (H-B). The quality of the enrolled studies was assessed by NOS and presented in **Table [S1](#SM0){ref-type="supplementary-material"}**.

Quantitative synthesis
----------------------

Results of the association between polymorphisms in genes of PI3K/Akt pathway and PCa risk were showed in **Table [2](#T2){ref-type="table"} and Table [S2](#SM0){ref-type="supplementary-material"}.** However, the pooled results suggested negative associations between all the 13 polymorphisms in six genes of PI3K/Akt signaling pathway and PCa risk.

However, in the subgroup analysis by ethnicity, we found that *IL-6*-rs1800795 polymorphism was associated with an increased risk of PCa in dominant model for Caucasian population (MM + MW vs. WW: OR=1.245, 95%CI = 1.176-1.318, *P* \< 0.001, **Figure [1](#F1){ref-type="fig"}A**). Furthermore, in the subgroup analysis by source of control, we also found an increased risk of PCa for P-B groups in dominant model (MM + MW vs. WW; OR = 1.246, 95%CI = 1.177-1.319, *P* \< 0.001, **Figure [1](#F1){ref-type="fig"}B**). Although subgroup analyses were also conducted for other polymorphisms in genes of PI3K/Akt signaling pathway, negative results were found.

Sensitivity analysis and Publication bias
-----------------------------------------

Sensitivity analysis was conducted by excluding one single study each time, and no evidence was observed suggesting pooled ORs shift (**Table [S3](#SM0){ref-type="supplementary-material"}**). In addition, we used Begg\'s funnel plot and Egger\'s regression test to assess potential publication bias. As for *TLR4*-rs1927914, *TLR4*-rs10759932, *TLR4*-rs2149356, *TLR4*-rs4986790, *TLR4*-rs11536889, *TLR4*-rs7873784, *VEGF*-rs833061, *VEGF*-rs1570360, *IRS1*-rs1801278, *FGFR4*-rs351855, *IL-6*-rs1800796, *IGF1*-(CA)19 polymorphisms, no evidence of publication bias was identified by viewing the shape of Begg\'s funnel plot, which was further validated by Egger\'s regression test. However, for *IL-6*-rs1800795 polymorphism, potential publication bias was existed (*P* = 0.016)**(Table [S4](#SM0){ref-type="supplementary-material"})**. In that case, we further conducted sensitivity analysis by using the trim and fill method[@B55], and imputed studies provide a symmetrical funnel plot (data not shown), indicating publication bias was not existed.

Discussion
==========

Recently, enormous studies suggested that polymorphisms in genes of PI3K/Akt pathway may play an important role in the prevention, diagnosis and treatment of PCa. For example, *TLR4* is the main component of *TLRs* and has been positively investigated in inflammation and cancer. Previous studies had confirmed that two polymorphisms in *TLR4* (rs4986790 and rs4986791) owned susceptibility to various type of cancers, including PCa[@B56]. *VEGF* is the most significant regulator of angiogenesis in human, and it plays a significant role in the occurrence and development of PCa[@B49],[@B50]. It had been identified that there were many genetic variants in the *VEFG* gene[@B57], but the conclusions were remained inconsistent[@B23],[@B52]-[@B57]. The *IRS1* gene Gly972Arg (rs1801278) polymorphisms had been found a significant association with increased cancer risk[@B58]. *In vitro* studies have proved that the *IRS1* gene rs1801278 polymorphism impaired insulin-stimulated signaling pathway, especially through the PI3-kinase pathway[@B59]. What\'s more, as a docking protein for the insulin-like growth factor receptor 1 (IGF1R) [@B60],[@B61], IRS1 controls IGF-1 mediated cell growth and survival[@B60]. Thus the polymorphisms of *IGF-1* gene also related to the cancer risks including PCa[@B61]. Fibroblast growth factor receptor 4 (FGFR4) is one member of the family of fibroblast growth factor receptors (FGFR1-4), which displays complicated biological activities such as angiogenic and mitogenic activity. Previous study had presented that its gene polymorphism was related to PCa risks[@B62]. The human*IL-6* gene encodes IL-6, a cytokine which adjusts the level of inflammation. Two polymorphisms on the promoter region of IL-6, rs1800795 (-174G/C) and rs1800796 (-572C/G) have been identified to be associated with IL-6 production[@B63]. And these association with risks of cancer have been published in a previous meta-analysis[@B64],[@B65]. Furthermore, although these studies and meta-analysis provided some clues for separate polymorphisms in one or more genes of PI3K/Akt pathway and PCa risk, these results were not fully consistent, or even contradictory at sometimes. Therefore, we performed current meta-analysis in order to provide a comprehensive accurate assessment of the associations of these polymorphisms in genes of PI3K/Akt pathway with PCa risk. To the best of our knowledge, this is the first pooled study that analyzed the associations between 13 polymorphisms in six pivotal genes of PI3K/Akt pathway and PCa risk. Meanwhile, further analyses were conducted in different subgroups to explore the potential associations or heterogeneity sources.

Nevertheless, overall results revealed that none of these polymorphisms was associated with PCa risk. Then, we performed subgroup analysis based on ethnicity, source of control (population-based or hospital-based) and HWE status (conform or not conform). For *IL-6-*rs1800795 polymorphism, when the stratification analysis was conducted by ethnicity, we found that a statistically significant increased risk of PCa was identified in the dominant model for Caucasians. However, in the meta-analysis conducted by *Liu et al.*[@B66], they did not reveal a significant connection between *IL-6*-rs1800795 polymorphism and PCa risk in Caucasian. For other polymorphisms, null association was uncovered when the stratified analyses were conducted based on ethnicity, source of control or HWE status.

Although we were surprised by these negative results, the high quality of these included studies and the substantial amount of data strengthened the possibility that the lack of association was not caused by chance. For those comparisons that did not exhibit a statistically significant association, may be as a result of the characteristics of low-penetrance genes. Moreover, although these polymorphisms assessed were appropriate candidates, they only account for some of the factors, and ignored other factors such as obesity, diet and environment. We summarized the advantages of current work. Firstly, although many meta-analyses provided some clues for separate polymorphisms in one or more genes of PI3K/Akt pathway and PCa risk, the current one provide a more comprehensive accurate assessment of the associations of all available polymorphisms in genes of PI3K/Akt pathway with PCa risk. To the best of our knowledge, this is the first pooled study that analyzed the associations between 13 polymorphisms in six pivotal genes of PI3K/Akt pathway and PCa risk. Secondly, we applied classic formula to adjust the *P*-values, which removed most of the marginal or false-positive *P*-values, making the final pool results more convincing. Thirdly, we found *IL-6*-rs1800795 polymorphism could be served as a risk prediction marker for Caucasian PCa patients. Our results provided some clues for the future clinical research that polymorphisms in genes of this pathway may not suitable for high-risk prostate cancer patients\' screening. There are also several deficiencies that should be addressed. Firstly, other factors such as the density of prostate-specific antigen (PSA), living conditions and histological types, the stage and grades of PCa should be included to get more precise results. Secondly, for many polymorphisms of these inclusive genes, relatively small samples were included for the assessment, such as rs1927914 polymorphism. Finally, we ignored that there were many individual characters such as age, obesity, alcohol, consumption and other lifestyle risk factors which could influence our conclusions.

Overall, our meta-analysis provided no statistically significant association between the 13 polymorphisms in six genes of PI3K/Akt signaling pathway and PCa risk. However, a significantly increased risk of PCa in Caucasian individuals was identified for *IL-6*-rs1800795 polymorphism in the dominant model. Due to the limitations of these included studies, as well as the risk factors we ignored, further well-designed studies with larger samples are warranted to verify our findings.
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**Forest plots of the association between *IL-6*-rs1800795 polymorphism and prostate cancer risk.** Subgroup analysis by ethnicity (A) and source of control (B).
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Characteristics of the enrolled studies.

  Gene      SNP          First Author            Year   Genotyping Method   Ethnicity   Source of Control   Case   Control                              
  --------- ------------ ----------------------- ------ ------------------- ----------- ------------------- ------ --------- ------ ------ ------ ----- ---
  *TLR4*    rs1927914    Chen *et al.*           2005   MassARRAY           Caucasian   P-B                 297    301       60     290    288    91    Y
            rs1927914    Zheng *et al.*          2004   MassARRAY           Caucasian   P-B                 625    596       154    341    354    81    Y
            rs1927914    Song *et al.*           2009   PCR-RFLP            Asian       H-B                 69     54        14     48     87     7     N
            rs10759932   Chen *et al.*           2005   MassARRAY           Caucasian   P-B                 511    155       11     472    197    12    Y
            rs10759932   Zheng *et al.*          2004   MassARRAY           Caucasian   P-B                 991    350       34     571    194    13    Y
            rs10759932   Shui *et al.*           2012   MALDI-TOF           Caucasian   P-B                 897    260       27     908    244    27    N
            rs10759932   Cheng *et al.*          2007   Sequencing          Caucasian   H-B                 370    117       119    358    143    4     N
            rs2149356    Chen *et al.*           2005   MassARRAY           Caucasian   P-B                 320    286       61     305    275    91    N
            rs2149356    Zheng *et al.*          2004   MassARRAY           Caucasian   P-B                 603    423       136    331    224    74    N
            rs2149356    Shui *et al.*           2012   MALDI-TOF           Caucasian   P-B                 579    489       106    576    460    119   Y
            rs2149356    Cheng *et al.*          2007   Sequencing          Caucasian   H-B                 197    223       85     210    213    82    N
            rs4986790    Chen *et al.*           2005   MassARRAY           Caucasian   P-B                 588    66        3      605    59     5     N
            rs4986790    Cheng *et al.*          2007   TaqMan              Caucasian   H-B                 439    66        1      456    48     2     Y
            rs4986790    Wang *et al.*           2009   TaqMan              Caucasian   P-B                 230    24        0      216    35     0     Y
            rs4986790    Balistreri *et al.*     2010   PCR-RFLP            Caucasian   H-B                 49     1         0      111    13     1     Y
            rs11536889   Chen *et al.*           2005   MassARRAY           Caucasian   P-B                 515    167       10     513    159    15    Y
            rs11536889   Zheng *et al.*          2004   MassARRAY           Caucasian   P-B                 1047   318       15     625    141    12    Y
            rs11536889   Shui *et al.*           2012   MALDI-TOF           Caucasian   P-B                 909    202       32     897    291    27    Y
            rs11536889   Cheng *et al.*          2007   Sequencing          Caucasian   H-B                 385    105       16     401    93     12    N
            rs11536889   Wang *et al.*           2009   TaqMan              Caucasian   P-B                 178    79        7      175    71     6     Y
            rs7873784    Chen *et al.*           2005   MassARRAY           Caucasian   P-B                 475    178       16     459    180    30    N
            rs7873784    Shui *et al.*           2012   MALDI-TOF           Caucasian   P-B                 887    295       24     861    302    19    Y
            rs7873784    Cheng *et al.*          2007   Sequencing          Caucasian   H-B                 362    130       13     346    146    14    Y
  *IL-6*    rs1800796    Wang *et al.*           2009   TaqMan              Caucasian   P-B                 233    19        1      225    25     0     Y
            rs1800796    Pierce *et al.*         2009   TaqMan              Caucasian   P-B                 156    19        0      1740   192    2     Y
            rs1800796    Pierce *et al.*         2009   TaqMan              Mixed       P-B                 37     2         1      251    41     6     N
            rs1800796    Sun *et al.*            2004   Microarray          Caucasian   P-B                 1226   109       2      675    74     4     Y
            rs1800795    Mandal *et al.*         2014   PCR                 Mixed       H-B                 108    44        12     74     44     22    N
            rs1800795    Zhang *et al.*          2010   Sequenom            Mixed       P-B                 80     86        27     100    75     22    Y
            rs1800795    Zabaleta *et al.*       2009   TaqMan              Caucasian   H-B                 19     34        21     126    163    112   N
            rs1800795    Zabaleta *et al.*       2009   TaqMan              Mixed       H-B                 10     2         3      41     10     6     N
            rs1800795    Dossus *et al.*         2010   GoldenGate          Caucasian   P-B                 3594   3218      1125   3832   3402   274   N
            rs1800795    Wang *et al.*           2009   TaqMan              Caucasian   P-B                 91     116       43     84     128    40    Y
            rs1800795    Moore *et al.*          2009   TaqMan              Caucasian   P-B                 191    485       281    196    401    250   Y
            rs1800795    Pierce *et al.*         2009   TaqMan              Caucasian   P-B                 48     96        31     648    805    305   N
            rs1800795    Pierce *et al.*         2009   TaqMan              Mixed       P-B                 34     5         1      216    43     1     Y
            rs1800795    Kesarwani *et al.*      2008   PCR                 Asia        H-B                 102    84        14     103    87     10    Y
            rs1800795    Bao *et al.*            2008   TaqMan              Asia        P-B                 136    0         0      120    0      0     N
            rs1800795    Michaud *et al.*        2006   TaqMan              Caucasian   P-B                 170    223       91     230    293    90    Y
  *IGF1*    (CA)19       Chu *et al.*            2006   Sequenom            Caucasian   P-B                 75     28        21     73     76     25    Y
            (CA)19       Chu *et al.*            2006   Sequenom            Mixed       P-B                 4      17        17     2      20     16    Y
            (CA)19       Neuhausen *et al.*      2005   PCR                 Caucasian   H-B                 78     86        29     107    124    32    Y
            (CA)19       Schildkraut *et al.*    2005   PCR                 Mixed       P-B                 20     39        35     28     33     20    Y
            (CA)19       Norihiko *et al.*       2005   PCR                 Asian       H-B                 155    130       18     289    172    20    Y
            (CA)19       Friedrichsen *et al.*   2005   PCR-RFLP            Mixed       P-B                 73     289       219    64     237    219   Y
            (CA)19       Nam *et al.*            2003   PCR-RFLP            Mixed       P-B                 64     230       189    103    253    192   Y
            (CA)19       Wenndy *et al.*         2007   PCR                 Mixed       H-B                 324    28        49     289    26     51    N
  *VEGF*    rs833061     Fukuda *et al.*         2007   PCR-RFLP            Asian       H-B                 143    103       24     132    97     23    Y
            rs833061     Onen *et al.*           2008   PCR-RFLP            Mixed       P-B                 33     89        11     50     94     13    N
            rs833061     Lin *et al.*            2003   PCR-RFLP            Asian       H-B                 60     32        4      43     72     4     N
            rs833061     Onen *et al.*           2008   PCR-RFLP            Caucasian   P-B                 33     89        11     50     94     13    N
            rs1570360    Sfar *et al.*           2006   RFLP-PCR            Caucasian   H-B                 58     37        6      36     50     14    Y
            rs1570360    Jacobs *et al.*         2008   TaqMan              Caucasian   P-B                 557    489       126    210    194    54    Y
            rs1570360    McCarron *et al.*       2013   TaqMan              Caucasian   P-B                 114    109       15     120    109    34    Y
  *IRS1*    rs1801278    Andrea *et al.*         2011   PCR                 Caucasian   H-B                 56     5         0      106    12     1     Y
            rs1801278    Fall *et al.*           2008   PCR                 Mixed       H-B                 489    73        2      662    90     6     Y
            rs1801278    Li *et al.*             2013   PCR                 Mixed       P-B                 386    50        2      422    65     1     Y
            rs1801278    Neuhausen *et al.*      2005   PCR                 Caucasian   P-B                 118    50        12     160    81     14    Y
  *FGFR4*   rs351855     FitzGerald *et al.*     2009   SNPlex™             Caucasian   P-B                 587    544       123    631    496    124   Y
            rs351855     FitzGerald *et al.*     2009   SNPlex™             Mixed       P-B                 104    39        3      60     18     2     Y
            rs351855     Lee *et al.*            2010   TaqMan              Caucasian   P-B                 183    182       32     235    167    37    Y
            rs351855     Zhiyong *et al.*        2010   PCR                 Asian       H-B                 133    196       163    67     152    125   Y

**Note:** Hardy-Weinberg equilibrium (HWE); population-based (P-B); hospital-based (H-B); Mixed: more than two descendants; W: wild allele; M: mutated allele; PCR: Polymerase chain reaction; RFLP-PCR: restriction fragment length polymorphism-Polymerase chain reaction

###### 

Details of the association between *IL-6*-rs1800795 polymorphism and prostate cancer risk.

  Comparison       Subgroup    N    *P*~H~   *P*~Z~        Random                Fixed
  ---------------- ----------- ---- -------- ------------- --------------------- ---------------------
  M vs. W          Overall     11   0.000    0.207         1.108 (0.945-1.300)   1.347 (1.292-1.403)
  M vs. W          Asia        1    1.000    0.692         1.065 (0.780-1.453)   1.065 (0.780-1.453)
  M vs. W          Caucasian   6    0.000    0.071         1.171 (0.986-1.391)   1.370 (1.313-1.429)
  M vs. W          H-B         4    0.020    0.772         0.946 (0.648-1.380)   0.926 (0.765-1.122)
  M vs. W          P-B         7    0.000    0.038         1.188 (1.010-1.397)   1.371 (1.315-1.431)
  M vs. W          N           5    0.000    0.528         1.106 (0.809-1.514)   1.430 (1.365-1.499)
  M vs. W          Y           6    0.710    0.053         1.090 (0.999-1.190)   1.090 (0.999-1.190)
  WM vs. WW        Overall     11   0.103    0.269         1.080 (0.951-1.227)   1.033 (0.975-1.096)
  WM vs. WW        Asia        1    1.000    0.903         0.975 (0.650-1.463)   0.975 (0.650-1.463)
  WM vs. WW        Caucasian   6    0.061    0.177         1.112 (0.953-1.296)   1.036 (0.975-1.100)
  WM vs. WW        H-B         4    0.380    0.678         0.941 (0.709-1.250)   0.943 (0.716-1.243)
  WM vs. WW        P-B         7    0.054    0.156         1.116 (0.959-1.299)   1.038 (0.978-1.102)
  WM vs. WW        N           5    0.048    0.512         1.101 (0.826-1.466)   1.022 (0.958-1.089)
  WM vs. WW        Y           6    0.353    0.217         1.088 (0.935-1.266)   1.092 (0.950-1.256)
  MM vs. WW        Overall     11   0.000    0.211         1.411 (0.823-2.421)   2.609 (2.359-2.885)
  MM vs. WW        Asia        1    1.000    0.428         1.414 (0.600-3.329)   1.414 (0.600-3.329)
  MM vs. WW        Caucasian   6    0.000    0.214         1.529 (0.783-2.986)   2.778 (2.502-3.085)
  MM vs. WW        H-B         4    0.043    0.960         0.982 (0.473-2.036)   0.912 (0.606-1.372)
  MM vs. WW        P-B         7    0.000    0.119         1.671 (0.877-3.184)   2.790 (2.513-3.097)
  MM vs. WW        N           5    0.000    0.464         1.431 (0.548-3.734)   3.601 (3.177-4.082)
  MM vs. WW        Y           6    0.682    0.025         1.233 (1.028-1.479)   1.231 (1.027-1.477)
  WM + MM vs. WW   Overall     11   0.047    0.040         1.147 (1.006-1.308)   1.228 (1.162-1.298)
  WM + MM vs. WW   Asia        1    1.000    0.920         1.020 (0.689-1.510)   1.020 (0.689-1.510)
  WM + MM vs. WW   Caucasian   6    0.292    **\<0.001**   1.224 (1.113-1.346)   1.245 (1.176-1.318)
  WM + MM vs. WW   H-B         4    0.114    0.505         0.936 (0.631-1.390)   0.917 (0.710-1.184)
  WM + MM vs. WW   P-B         7    0.296    **\<0.001**   1.227 (1.117-1.349)   1.246 (1.177-1.319)
  WM + MM vs. WW   N           5    0.017    0.359         1.150 (0.853-1.552)   1.252 (1.178-1.331)
  WM + MM vs. WW   Y           6    0.500    0.082         1.124 (0.985-1.283)   1.124 (0.985-1.282)
  MM vs. WM + WW   Overall     11   0.000    0.315         1.331 (0.762-2.323)   2.292 (2.093-2.509)
  MM vs. WM + WW   Asia        1    1.000    0.402         1.430 (0.620-3.300)   1.430 (0.620-3.300)
  MM vs. WM + WW   Caucasian   6    0.000    0.366         1.388 (0.682-2.826)   2.404 (2.189-2.640)
  MM vs. WM + WW   H-B         4    0.087    0.866         0.949 (0.516-1.746)   0.899 (0.618-1.308)
  MM vs. WM + WW   P-B         7    0.000    0.218         1.543 (0.774-3.074)   2.429 (2.211-2.669)
  MM vs. WM + WW   N           5    0.000    0.585         1.323 (0.485-3.606)   3.390 (3.015-3.812)
  MM vs. WM + WW   Y           6    0.449    0.171         1.114 (0.956-1.298)   1.112 (0.955-1.296)

**Note:** Hardy-Weinberg equilibrium (HWE); P-B: population-based; H-B: hospital-based; Y: Studies conformed to HWE; N: studies did not conform to HWE; Mixed: more than two descendant; ^\*^*P* value less than \[0.05/ (5\*13)\] means statistically significant.
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